Selected Publications

  1. Belgiovine C, Frapolli R, Liguori M, Digifico E, Colombo FS, Meroni M, Allavena P, D’Incalci M. Inhibition of tumor-associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti-PD-1 therapy (2021) Eur J Immunol 27.
  2. Morosi L, Meroni M, Ubezio P, Fuso Nerini I, Minoli L, Porcu L, Panini N, Colombo M, Blouw B, Kang DW, Davoli E, Zucchetti M, D’Incalci M, Frapolli R. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models (2021) J Exp Clin Cancer Res, 10;40(1):286.
  3. Mannarino, L., Craparotta, I., Ballabio, S., Frapolli, R., Meroni, M., Bello, E., Panini, N., Callari, M., Sanfilippo, R., Casali, P.G., Barisella, M., Fabbroni, C., Marchini, S., D’Incalci, M. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma (2021) Genomics, 113 (5), pp. 3439-3448.
  4. Paracchini, L., Beltrame, L., Grassi, T., Inglesi, A., Fruscio, R., Landoni, F., Ippolito, D., Marchette, M.D., Paderno, M., Adorni, M., Jaconi, M., Romualdi, C., D’Incalci, M., Siravegna, G., Marchini, S. Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer (2021) Clinical Cancer Research, 27 (9), pp. 2549-2560.
  5. Fuso Nerini, I., Roca, E., Mannarino, L., Grosso, F., Frapolli, R., D’Incalci, M. Is DNA repair a potential target for effective therapies against malignant mesothelioma? (2020) Cancer Treatment Reviews, 90, art. no. 102101.
  6. Digifico, E., Erreni, M., Colombo, F.S., Recordati, C., Migliore, R., Frapolli, R., D’Incalci, M., Belgiovine, C., Allavena, P. Optimization of a luciferase-expressing non-invasive intrapleural model of malignant mesothelioma in immunocompetent mice (2020) Cancers, 12 (8), art. no. 2136, pp. 1-14.
  7. Benvenuto, G., Todeschini, P., Paracchini, L., Calura, E., Fruscio, R., Romani, C., Beltrame, L., Martini, P., Ravaggi, A., Ceppi, L., Sales, G., Donati, F., Perego, P., Zanotti, L., Ballabio, S., Grassi, T., Delle Marchette, M., Tognon, G., Sartori, E., Adorni, M., Odicino, F., D’Incalci, M., Bignotti, E., Romualdi, C., Marchini, S. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer (2020) International Journal of Cancer, 147 (2), pp. 565-574.
  8. Paracchini, L., Pesenti, C., Delle Marchette, M., Beltrame, L., Bianchi, T., Grassi, T., Buda, A., Landoni, F., Ceppi, L., Bosetti, C., Paderno, M., Adorni, M., Vicini, D., Perego, P., Leone, B.E., D’Incalci, M., Marchini, S., Fruscio, R. Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis (2020) JAMA Network Open, 3 (7), art. no. e207566.
  9. Morosi, L., Matteo, C., Ceruti, T., Giordano, S., Ponzo, M., Frapolli, R., Zucchetti, M., Davoli, E., D’Incalci, M., Ubezio, P. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging (2020) International Journal of Biological Sciences, 16 (8), pp. 1363-1375.
  10. Frapolli, R., Bello, E., Ponzo, M., Craparotta, I., Mannarino, L., Ballabio, S., Marchini, S., Carrassa, L., Ubezio, P., Porcu, L., Brich, S., Sanfilippo, R., Casali, P.G., Gronchi, A., Pilotti, S., D’Incalci, M. Combination of PPARg agonist pioglitazone and trabectedin induce adipocyte differentiation to overcome trabectedin resistance in myxoid liposarcomas (2019) Clinical Cancer Research, 25 (24), pp. 7565-7575.
  11. Calura, E., Ciciani, M., Sambugaro, A., Paracchini, L., Benvenuto, G., Milite, S., Martini, P., Beltrame, L., Zane, F., Fruscio, R., Marchette, M.D., Borella, F., Tognon, G., Ravaggi, A., Katsaros, D., Bignotti, E., Odicino, F., D’Incalci, M., Marchini, S., Romualdi, C. Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study (2019) Cells, 8 (12).
  12. Ballabio, S., Craparotta, I., Paracchini, L., Mannarino, L., Corso, S., Pezzotta, M.G., Vescio, M., Fruscio, R., Romualdi, C., Dainese, E., Ceppi, L., Calura, E., Pileggi, S., Siravegna, G., Pattini, L., Martini, P., delle Marchette, M., Mangioni, C., Ardizzoia, A., Pellegrino, A., Landoni, F., D’Incalci, M., Beltrame, L., Marchini, S. Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3 (2019) International Journal of Cancer, 145 (10), pp. 2670-2681.
  13. Colombo, N., Zaccarelli, E., Baldoni, A., Frezzini, S., Scambia, G., Palluzzi, E., Tognon, G., Lissoni, A.A., Rubino, D., Ferrero, A., Farina, G., Negri, E., Pesenti Gritti, A., Galli, F., Biagioli, E., Rulli, E., Poli, D., Gerardi, C., Torri, V., Fossati, R., D‘Incalci, M. Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer (2019) British Journal of Cancer, 121 (9), pp. 744-750.
  14. Bello, E., Brich, S., Craparotta, I., Mannarino, L., Ballabio, S., Gatta, R., Marchini, S., Carrassa, L., Matteo, C., Sanfilippo, R., Gronchi, A., Casali, P.G., Pilotti, S., D’Incalci, M., Frapolli, R. Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin (2019) British Journal of Cancer, 121 (6), pp. 464-473.
  15. Falcetta, F., Morosi, L., Ubezio, P., Giordano, S., Decio, A., Giavazzi, R., Frapolli, R., Prasad, M., Franceschi, P., D’Incalci, M., Davoli, E. Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging (2018) Analytica Chimica Acta, 1042, pp. 1-10.
  16. Gadducci, A., Grosso, F., Scambia, G., Raspagliesi, F., Colombo, N., Grignani, G., Casali, P., Sanfilippo, R., Buonadonna, A., Santoro, A., Bruzzone, M., Artioli, G., Lorusso, D., Biagioli, E., Fossati, R., Galli, F., Negri, E., Rulli, E., Torri, V., D’Incalci, M. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) British Journal of Cancer, 119 (5), pp. 565-571.
  17. Capasso Palmiero, U., Morosi, L., Bello, E., Ponzo, M., Frapolli, R., Matteo, C., Ferrari, M., Zucchetti, M., Minoli, L., De Maglie, M., Romanelli, P., Morbidelli, M., D’Incalci, M., Moscatelli, D. Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin (2018) Journal of Controlled Release, 276, pp. 140-149.
  18. Garattini, S., Fuso Nerini, I., D’Incalci, M. Not only tumor but also therapy heterogeneity (2018) Annals of Oncology, 29 (1), pp. 13-18.
  19. Erba, E., Romano, M., Gobbi, M., Zucchetti, M., Ferrari, M., Matteo, C., Panini, N., Colmegna, B., Caratti, G., Porcu, L., Fruscio, R., Perlangeli, M.V., Mezzanzanica, D., Lorusso, D., Raspagliesi, F., D’Incalci, M. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein (2017) Biochemical Pharmacology, 144, pp. 52-62.
  20. Morosi, L., Giordano, S., Falcetta, F., Frapolli, R., Licandro, S.A., Matteo, C., Zucchetti, M., Ubezio, P., Erba, E., Visentin, S., D’Incalci, M., Davoli, E. Application of 3D Mass Spectrometry Imaging to TKIs (2017) Clinical Pharmacology and Therapeutics, 102 (5), pp. 748-751.
  21. Belgiovine, C., Bello, E., Liguori, M., Craparotta, I., Mannarino, L., Paracchini, L., Beltrame, L., Marchini, S., Galmarini, C.M., Mantovani, A., Frapolli, R., Allavena, P., D’Incalci, M. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models (2017) British Journal of Cancer, 117 (5), pp. 628-638.
  22. Martini, P., Paracchini, L., Caratti, G., Mello-Grand, M., Fruscio, R., Beltrame, L., Calura, E., Sales, G., Ravaggi, A., Bignotti, E., Odicino, F.E., Sartori, E., Perego, P., Katsaros, D., Craparotta, I., Chiorino, G., Cagnin, S., Mannarino, L., Ceppi, L., Mangioni, C., Ghimenti, C., D’Incalci, M., Marchini, S., Romualdi, C. LncRNAs as novel indicators of patients’ prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study (2017) Clinical Cancer Research, 23 (9), pp. 2356-2366.
  23. Todeschini, P., Salviato, E., Paracchini, L., Ferracin, M., Petrillo, M., Zanotti, L., Tognon, G., Gambino, A., Calura, E., Caratti, G., Martini, P., Beltrame, L., Maragoni, L., Gallo, D., Odicino, F.E., Sartori, E., Scambia, G., Negrini, M., Ravaggi, A., D’Incalci, M., Marchini, S., Bignotti, E., Romualdi, C. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts (2017) Cancer Letters, 388, pp. 320-327.
  24. Uboldi, S., Craparotta, I., Colella, G., Ronchetti, E., Beltrame, L., Vicario, S., Marchini, S., Panini, N., Dagrada, G., Bozzi, F., Pilotti, S., Galmarini, C.M., D’Incalci, M., Gatta, R. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells (2017) BMC Cancer, 17 (1), art. no. 107.
  25. Calura, E., Paracchini, L., Fruscio, R., DiFeo, A., Ravaggi, A., Peronne, J., Martini, P., Sales, G., Beltrame, L., Bignotti, E., Tognon, G., Milani, R., Clivio, L., Dell’Anna, T., Cattoretti, G., Katsaros, D., Sartori, E., Mangioni, C., Ardighieri, L., D’Incalci, M., Marchini, S., Romualdi, C. A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment (2016) Annals of Oncology, 27 (8), pp. 1511-1519.
  26. Belgiovine, C., D’Incalci, M., Allavena, P., Frapolli, R. Tumor-associated macrophages and anti-tumor therapies: complex links (2016) Cellular and Molecular Life Sciences, 73 (13), pp. 2411-2424.
  27. Petrillo, M., Zannoni, G.F., Beltrame, L., Martinelli, E., DiFeo, A., Paracchini, L., Craparotta, I., Mannarino, L., Vizzielli, G., Scambia, G., D’Incalci, M., Romualdi, C., Marchini, S. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: A retrospective longitudinal analysis using matched tumor biopsies (2016) Annals of Oncology, 27 (4), pp. 625-634.
  28. Larsen, A.K., Galmarini, C.M., D’Incalci, M. Unique features of trabectedin mechanism of action (2016) Cancer Chemotherapy and Pharmacology, 77 (4), pp. 663-671.
  29. D’Incalci, M., Zambelli, A. Trabectedin for the treatment of breast cancer (2016) Expert Opinion on Investigational Drugs, 25 (1), pp. 105-115.
  30. Colmegna, B., Uboldi, S., Frapolli, R., Licandro, S.A., Panini, N., Galmarini, C.M., Badri, N., Spanswick, V.J., Bingham, J.P., Kiakos, K., Erba, E., Hartley, J.A., D’Incalci, M. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin (2015) British Journal of Cancer, 113 (12), pp. 1687-1693.
  31. Beltrame, L., Di Marino, M., Fruscio, R., Calura, E., Chapman, B., Clivio, L., Sina, F., Mele, C., Iatropoulos, P., Grassi, T., Fotia, V., Romualdi, C., Martini, P., Noris, M., Paracchini, L., Craparotta, I., Petrillo, M., Milani, R., Perego, P., Ravaggi, A., Zambelli, A., Ronchetti, E., D’Incalci, M., Marchini, S. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: A retrospective study (2015) Annals of Oncology, 26 (7), pp. 1363-1371.
  32. D’Incalci, M., Badri, N., Galmarini, C.M., Allavena, P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment (2014) British Journal of Cancer, 111 (4), pp. 646-650.
  33. Calura, E., Martini, P., Sales, G., Beltrame, L., Chiorino, G., D’Incalci, M., Marchini, S., Romualdi, C. Wiring miRNAs to pathways: A topological approach to integrate miRNA and mRNA expression profiles (2014) Nucleic Acids Research, 42 (11).
  34. Parikh, A., Lee, C., Joseph, P., Marchini, S., Baccarini, A., Kolev, V., Romualdi, C., Fruscio, R., Shah, H., Wang, F., Mullokandov, G., Fishman, D., D’Incalci, M., Rahaman, J., Kalir, T., Redline, R.W., Brown, B.D., Narla, G., Difeo, A. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition (2014) Nature Communications, 5, art. no. 2977.
  35. Fuso Nerini, I., Morosi, L., Zucchetti, M., Ballerini, A., Giavazzi, R., D’incalci, M. Intratumor heterogeneity and its impact on drug distribution and sensitivity (2014) Clinical Pharmacology and Therapeutics, 96 (2), pp. 224-238.
  36. D’Incalci, M. Trabectedin mechanism of action: What’s new? (2013) Future Oncology, 9 (12 SUPPL.), pp. 5-10.
  37. Di Giandomenico, S., Frapolli, R., Bello, E., Uboldi, S., Licandro, S.A., Marchini, S., Beltrame, L., Brich, S., Mauro, V., Tamborini, E., Pilotti, S., Casali, P.G., Grosso, F., Sanfilippo, R., Gronchi, A., Mantovani, R., Gatta, R., Galmarini, C.M., Sousa-Faro, J.M.F., D’incalci, M. Mode of action of trabectedin in myxoid liposarcomas (2013) Oncogene, 33 (44), pp. 5201-5210.
  38. Romano, M., Frapolli, R., Zangarini, M., Bello, E., Porcu, L., Galmarini, C.M., García-Fernández, L.F., Cuevas, C., Allavena, P., Erba, E., D’Incalci, M. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104) (2013) International Journal of Cancer, 133 (9), pp. 2024-2033.
  39. Morosi, L., Spinelli, P., Zucchetti, M., Pretto, F., Carrà, A., D’Incalci, M., Giavazzi, R., Davoli, E. Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging (2013) PLoS ONE, 8 (8), art. no. e72532.
  40. Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Ravaggi, A., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., Fuso Nerini, I., Zanotti, L., Cavalieri, D., Cattoretti, G., Perego, P., Milani, R., Katsaros, D., Tognon, G., Sartori, E., Pecorelli, S., Mangioni, C., D’Incalci, M., Romualdi, C., Marchini, S. MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities (2013) Clinical Cancer Research, 19 (15), pp. 4114-4123.
  41. Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., Nebuloni, M., van Rooijen, N., Mortarini, R., Beltrame, L., Marchini, S., Fuso Nerini, I., Sanfilippo, R., Casali, P.G., Pilotti, S., Galmarini, C.M., Anichini, A., Mantovani, A., D’Incalci, M., Allavena, P. Role of Macrophage Targeting in the Antitumor Activity of Trabectedin (2013) Cancer Cell, 23 (2), pp. 249-262.
  42. Morosi, L., Zucchetti, M., D’Incalci, M., Davoli, E. Imaging mass spectrometry: Challenges in visualization of drug distribution in solid tumors (2013) Current Opinion in Pharmacology, 13 (5), pp. 807-812.
  43. D’Incalci, M., Frapolli, R., Germano, G., Allavena, P. New activities for the anti-tumor agent trabectedin: Taking two birds with one stone (2013) Oncotarget, 4 (4), pp. 496-497.
  44. Marchini, S., Fruscio, R., Clivio, L., Beltrame, L., Porcu, L., Fuso Nerini, I., Cavalieri, D., Chiorino, G., Cattoretti, G., Mangioni, C., Milani, R., Torri, V., Romualdi, C., Zambelli, A., Romano, M., Signorelli, M., Giandomenico, S.D., D’Incalci, M. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer (2013) European Journal of Cancer, 49 (2), pp. 520-530.
  45. Marchini, S., Poynor, E., Barakat, R.R., Clivio, L., Cinquini, M., Fruscio, R., Porcu, L., Bussani, C., D’Incalci, M., Erba, E., Romano, M., Cattoretti, G., Katsaros, D., Koff, A., Luzzatto, L. The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer (2012) Clinical Cancer Research, 18 (16), pp. 4313-4324.
  46. Uboldi, S., Bernasconi, S., Romano, M., Marchini, S., Fuso Nerini, I., Damia, G., Ganzinelli, M., Marangon, E., Sala, F., Clivio, L., Chiorino, G., Giandomenico, S.D., Rocchi, M., Capozzi, O., Margison, G.P., Watson, A.J., Caccuri, A.M., Pastore, A., Fossati, A., Mantovani, R., Grosso, F., Tercero, J.C., Erba, E., D’Incalci, M. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents (2012) International Journal of Cancer, 131 (1), pp. 59-69.
  47. Uboldi, S., Calura, E., Beltrame, L., Fuso Nerini, I., Marchini, S., Cavalieri, D., Erba, E., Chiorino, G., Ostano, P., D’Angelo, D., D’Incalci, M., Romualdi, C. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma (2012) PLoS ONE, 7 (4), art. no. e35423.
  48. Marchini, S., Cavalieri, D., Fruscio, R., Calura, E., Garavaglia, D., Fuso Nerini, I., Mangioni, C., Cattoretti, G., Clivio, L., Beltrame, L., Katsaros, D., Scarampi, L., Menato, G., Perego, P., Chiorino, G., Buda, A., Romualdi, C., D’Incalci, M. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections (2011) The Lancet Oncology, 12 (3), pp. 273-285.
  49. Sessa, C., D’Incalci, M. Trabectedin in ovarian cancer: Could we expect more? (2011) Annals of Oncology, 22 (1), pp. 7-8.
  50. Frapolli, R., Tamborini, E., Virdis, E., Bello, E., Tarantino, E., Marchini, S., Grosso, F., Sanfilippo, R., Gronchi, A., Tercero, J.C., Peloso, G., Casali, P., Pilotti, S., D’Incalci, M. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors (2010) Clinical Cancer Research, 16 (20), pp. 4958-4967.
  51. D’Incalci, M., Galmarini, C.M. A Review of trabectedin (ET-743): A unique mechanism of action (2010) Molecular Cancer Therapeutics, 9 (8), pp. 2157-2163.
  52. Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R., Casali, P.G., Gronchi, A., Virdis, E., Tarantino, E., Pilotti, S., Greco, A., Nebuloni, M., Galmarini, C.M., Tercero, J.C., Mantovani, A., D’Incalci, M., Allavena, P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells (2010) Cancer Research, 70 (6), pp. 2235-2244.